ClinicalTrials.gg

Program

itepekimab

Also written as “Itepekimab (SAR440340)”, “REGN3500” and “Itepekimab SAR440340”.

Its studies are mostly in Nasal Polyps · Pulmonary Disease, Chronic Obstructive · Asthma · Dermatitis, Atopic · Bronchiectasis, led by 2 companies.

Furthest: phase 3, since Dec 30, 202017 company-led studies, 3 open or runningNext primary completion: Feb 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi123 open or runningphase 3since Dec 30, 2020Dec 15, 2017Feb 17, 2027phase 3 · NCT07424144
Regeneron Pharmaceuticals50 open or runningphase 2since Nov 7, 2018Oct 25, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Oct 25, 2016.

  1. Dec 19, 2016Phase 1 study in AsthmaRegeneron Pharmaceuticals · NCT02999711 · 23 enrolled · United Kingdom
  2. Apr 4, 2017Phase 1 study in AsthmaRegeneron Pharmaceuticals · NCT03112577 · 32 enrolled · United States, United Kingdom
  3. Dec 15, 2017Sanofi's first study: phase 2 study in AsthmaNew to SanofiSanofi · NCT03387852 · 296 enrolled · United States, Argentina, Chile and more
  4. May 17, 2018Phase 2 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT03546907 · 343 enrolled · United States, Argentina, Australia and more
  5. Nov 7, 20182 phase 2 studies in Dermatitis, AtopicRegeneron Pharmaceuticals · NCT03736967, NCT03738423
  6. Dec 30, 2020Phase 3 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT04701983 · 1,127 enrolled · United States, Argentina, Bulgaria and more
  7. Feb 8, 2021Phase 3 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT04751487 · 1,234 enrolled · United States, Argentina, Brazil and more
  8. Apr 6, 2022Phase 2 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT05326412 · 49 enrolled · United States, Belgium, Brazil and more
  9. Jan 5, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveSanofi · NCT06208306 · 669 enrolled · United States, Argentina, Brazil and more
  10. Feb 20, 2024Phase 2 study in BronchiectasisSanofi · NCT06280391 · 314 enrolled · United States, Argentina, Brazil and more
  11. Nov 12, 2024Phase 2 study in Chronic Rhinosinusitis Without Nasal PolypsSanofi · NCT06691113 · 66 enrolled · United States, Argentina, Belgium and more
  12. Feb 14, 20252 phase 3 studies in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT06834360, NCT06834347
  13. Feb 13, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT07424144 · 59 enrolled · United States, Argentina, Australia and more
  14. Mar 16, 2026Phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT07484230

Ahead

  1. Feb 17, 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal PolypsSanofi · NCT07424144

TargetBeta

IL33 →read by rule
“Interleukin-33 inhibitor”ChEMBL 37, by rule

Other programs on IL33

ProgramCompanyFurthest phaseStudies
GSK3862995BGlaxoSmithKlinephase 25
ompekimigPfizerphase 23
HXN-1013ruleHelixon Biotechnology (Suzhou)phase 11
HY6725ruleNewsoara Biopharmaphase 11

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07484230Chronic Rhinosinusitis With Nasal Polyps3WithdrawnSanofiOct 20, 20270
NCT07424144Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more3Active, not recruitingSanofiFeb 17, 202759
NCT06834360Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Australia and more3Active, not recruitingSanofiSep 24, 2026216
NCT06834347Chronic Rhinosinusitis With Nasal Polyps · United States, Argentina, Austria and more3Active, not recruitingSanofiSep 23, 2026231
NCT06691113Chronic Rhinosinusitis Without Nasal Polyps · United States, Argentina, Belgium and more2CompletedSanofiMar 31, 202666
NCT06280391Bronchiectasis · United States, Argentina, Brazil and more2CompletedSanofiSep 16, 2025314
NCT06208306Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more3CompletedSanofiSep 10, 2026669
NCT05326412Pulmonary Disease, Chronic Obstructive · United States, Belgium, Brazil and more2CompletedSanofiMar 5, 202549
NCT04751487Pulmonary Disease, Chronic Obstructive · United States, Argentina, Brazil and more3CompletedSanofiApr 21, 20251,234
NCT04701983Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more3CompletedSanofiApr 11, 20251,127
NCT03738423Dermatitis, Atopic · United States, Australia, Canada and more2TerminatedRegeneron PharmaceuticalsMar 13, 2020129
NCT03736967Dermatitis, Atopic · United States, Belgium, Czechia and more2TerminatedRegeneron PharmaceuticalsMar 13, 2020206
NCT03546907Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more2CompletedSanofiOct 3, 2019343
NCT03387852Asthma · United States, Argentina, Chile and more2CompletedSanofiMar 21, 2019296
NCT03112577Asthma · United States, United Kingdom1CompletedRegeneron PharmaceuticalsMar 20, 201932
NCT02999711Asthma · United Kingdom1CompletedRegeneron PharmaceuticalsAug 30, 201823
NCT02958436Healthy Volunteers · Belgium1CompletedRegeneron PharmaceuticalsJun 18, 201740

How it is read

Names in the registry

  • “Itepekimab (SAR440340)”, 7 entries
  • “REGN3500”, 5 entries
  • “Itepekimab SAR440340”, 3 entries
  • “SAR440340”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.